ERBB2 and breast carcinoma: Studies in HER2-positive early breast cancer demonstrate that early dynamic changes in miR-148a-3p are significantly correlated with pathological complete response rates to trastuzumab-based chemotherapy, with patients whose miR-148a-3p levels increase correlating with higher pathological complete response rates (p=0.008) (42).